In this study, researchers evaluated the dose-response relationship between body mass index and the risk of developing pancreatic cancer by the age of 50 years.

In this meta-analysis, researchers evaluated the use and/or prolongation of ADT in men with non-metastatic prostate cancer undergoing definitive radiotherapy.

Investigators assessed PSA response to treatment at various time points for their relative abilities to predict disease progression in patients with metastatic hormone-sensitive prostate cancer (mHSPC ...

In patients naïve to HER2-targeted therapy, the objective response rate was 71% with a median duration of response of 9.2 months.

Status quo of choice between colonoscopy and FIT was cost-effective for White adults; CTC was cost-saving versus no screening.

In this systematic review, researchers examined the clinical features, diagnosis, treatment, and prognosis of pregnancy-associated colorectal cancer.

In the phase 3 HER2CLIMB-02 trial, researchers evaluated the efficacy and safety of tucatinib plus T-DM1 compared to T-DM1 alone in HER2+ locally advanced or metastatic breast cancer.

Cancer related cognitive impairment in patients can stem from the cancer itself as well as the therapies used to treat it.

The phase 2 ChonDRAgon study compared ozekibart to placebo in patients with metastatic or unresectable conventional chondrosarcoma who been diagnosed with radiographic progression.

In this cross-sectional analysis, researchers aimed to characterize the NIH trials affected by grant terminations under the Trump administration.

In the study, researchers evaluated county-level data across Pennsylvania for variables such as melanoma incidence, agricultural land use, agrochemical-treated acreage, ambient ultraviolet radiation, ...

Topline data were announced from a phase 3 trial evaluating giredestrant for the adjuvant treatment of estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ...